A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients

Clinical trial NCT06745583 · RECRUITING

Trial details

NCT number: NCT06745583
Sponsor: Elixiron Immunotherapeutics Inc.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Mild, Moderate, or Severe Alzheimer's Disease

Start date: 2024-12-16
Primary completion: 2026-12-01
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.